Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVXT RESEARCH THREAD -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (25)	2/6/2000 10:50:00 AM
From: chirodoc	Respond to of 35

Melanoma treatment updateII by: lty001 2/4/00 5:01 pm Vaccines shows exciting potential Vaccines trials continue to be promising. Leading researcher still disagree on what approaches work best. In a recent meta-analysis published in the Sothern Medical Journal of approaches to melanoma immunotherapy to date, experts said vaccines remain crude and difficult to formulate despite the fact that they are more effective than chmotherapy, radiotherapy, even Intron A. " The vaccine are exciting now," Dr Rapaport said. The following is my personal view: I have attended several dermatology conferences recently. MM vaccine has always been a red hot topic. Multiple MM vaccines(vac) are currently in clinical trials. All vaccines are prepared using one of two strategies. The strategies differs in the purity of the antigens(Ag) in the vaccine, and each has advantages and disadvantage. One is to construct vac fron whole cancer cells or their extracts. This has the advantage of incorporating all relevant ag in the vac, but the concentration of the ag is very low and the vac is crude. The second approach is to prepare the vac from a single or a limited number of purified tumor Ag. Such vac are very elegant and contains a high cencentration of the Ag, but we still do not know what the correct Ags is to use for the vaccine. In addition, vac containing a single or a limited number of Ags are less likely to be effective than those that stimulate immune responses to stimulate Ags on melanoma cells. My understanding is that M-VAX is the only MM vaccine in the world that has successfully utilized pts's own cancer cells on an individual bases, It has the advantages of the above two approaches while eliminating their disadvantages. AVXT's phase II data and their 9 years follow-up results are the most exciting and convincing result on this most devastating cancer, melignant melanoma treatment. This is why AVXT is one of my core holdings today. The end.